Mon, August 16, 2010
Fri, August 13, 2010
Thu, August 12, 2010
Wed, August 11, 2010
Tue, August 10, 2010
Mon, August 9, 2010
Fri, August 6, 2010
Thu, August 5, 2010
Wed, August 4, 2010
Tue, August 3, 2010
Mon, August 2, 2010
Fri, July 30, 2010
Thu, July 29, 2010
Wed, July 28, 2010
Tue, July 27, 2010
Mon, July 26, 2010

AMAG Pharmaceuticals, Inc. to Present at Canaccord Genuity 30th Annual Global Growth Conference


//health-fitness.news-articles.net/content/2010/ .. enuity-30th-annual-global-growth-conference.html
Published in Health and Fitness on Tuesday, August 3rd 2010 at 13:36 GMT by Market Wire   Print publication without navigation


LEXINGTON, Mass.--([ BUSINESS WIRE ])--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present an overview of the company at the Canaccord Genuity 30th Annual Global Growth Conference on August 10, 2010 at 9:00 a.m. ET. The conference is being held August 10-12, 2010 in Boston, MA.

A live webcast of the presentation will be accessible through the Investors section of the companya™s website at [ www.amagpharma.com ]. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for approximately two weeks.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG manufactures and sells two commercial products, Feraheme® (ferumoxytol) Injection for intravenous (IV) use and GastroMARK®, an oral contrast agent used in magnetic resonance imaging. For additional company information, please visit [ www.amagpharma.com ].

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.


Publication Contributing Sources